A Study of Durvalumab alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Trial Identifier: D933IC00003
Sponsor: AstraZeneca
NCTID:: NCT03459846
Start Date: March 2018
Primary Completion Date: October 2020
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
English Translation
French Translation
Korean Translation
Russian Translation
Spanish Translation
Spanish Translation
Traditional Chinese Taiwan Translation
Vietnamese Translation

Trial Locations

Country Location
CA, ON Hamilton, ON, CA, L8V 5C2
CA, ON Newmarket, ON, CA, L3Y 2P9
CA, ON Sudbury, ON, CA, P3E 5J1
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
ES Barcelona, ES, 08036
ES Madrid, ES, 28041
ES Madrid, ES, 08035
ES Málaga, ES, 29010
ES Santiago de Compostela, ES, 15706
KR Incheon, KR, 21565
KR Seoul, KR, 03722
KR Seoul, KR, 05505
KR Seoul, KR, 02841
KR Seoul, KR, 6351
RU Moscow, RU, 105077
RU Moscow, RU, 125367
RU Novosibirsk, RU, 630108
RU Omsk, RU, 644013
RU Saint Petersburg, RU, 195271
RU St. Petersburg, RU, 199178
RU St. Petersburg, RU, 194354
TW kaohsiung, TW, 807
TW Kaohsiung, TW
TW Taichung, TW, 40705
TW Tainan, TW, 704
TW Taipei, TW, 112
TW Taipei, TW, 10002
TW Taipei, TW, 104
TW Taoyuan City, TW, 333
US, AL Birmingham, AL, US, 35294
US, AZ Goodyear, AZ, US, 85338
US, FL Fort Myers, FL, US, 33901
US, FL St Petersburg, FL, US, 33705
US, FL Tampa, FL, US, 33612
US, KY Louisville, KY, US, 40202
US, NY Bronx, NY, US, 10461
US, NY Buffalo, NY, US, 14263
US, NY New Hyde Park, NY, US, 11042
US, NY New York, NY, US, 10065
US, PA Philadelphia, PA, US, 19124
US, TN Nashville, TN, US, 37232
US, WA Tacoma, WA, US, 98405
VN Hanoi, VN, 100000
VN Ho Chi Minh, VN, 700000
VN Ho Chi Minh city, VN, 700000